Drug Type Synthetic peptide |
Synonyms Antimicrobial Peptides PL-5, 抗菌肽PL-5, PL-5 |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC138H226N36O34 |
InChIKeyIUYWAZJIRQDBEJ-XECNVCPKSA-N |
CAS Registry850761-47-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Infectious Diseases | NDA/BLA | China | 24 Dec 2024 | |
Wound Infection | Phase 3 | China | 23 Aug 2021 | |
Bacterial Infections | Phase 2 | United States | 11 May 2023 | |
Secondary infection | Phase 2 | China | 28 Jul 2020 | |
Post-traumatic wound infection | Phase 2 | China | 24 Jul 2018 | |
Diabetic foot infection | Phase 2 | United States | - | |
Burn infections | Phase 1 | China | 07 Nov 2016 | |
Diabetic Foot | Phase 1 | China | 07 Nov 2016 | |
Folliculitis | Phase 1 | China | 07 Nov 2016 | |
Impetigo | Phase 1 | China | 07 Nov 2016 |
ADA2024 Manual | Not Applicable | 47 | PL-5 spray | duvtpqvbas(iwajiqelut) = myehiehphr vtcnliczqc (psvotqojcz ) View more | Positive | 21 Jun 2024 | |
Placebo | duvtpqvbas(iwajiqelut) = lrbmavihjv vtcnliczqc (psvotqojcz ) View more | ||||||
- | - | 570 | tryibqwwjd(clhpatabni) = oirroymgux twunrkshmn (nawodxyfsn ) View more | Non-inferior | 03 Jun 2024 | ||
磺胺嘧啶银 | tryibqwwjd(clhpatabni) = cgrnmsxaqp twunrkshmn (nawodxyfsn ) View more |